Literature DB >> 17092974

The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions.

E Wezenberg1, B G C Sabbe, W Hulstijn, G S F Ruigt, R J Verkes.   

Abstract

The study investigated whether four specified drugs would show similar patterns on tests considered to measure sedation. In addition, their drug-effect patterns on sedation and memory performance were compared to determine whether the sedative effects could be differentiated from the memory effects. Two double-blind, placebo-controlled, crossover studies, each with 16 healthy volunteers, were performed, one testing lorazepam (2.5 mg) and mirtazapine (15 mg) and the other olanzapine (10 mg) and haloperidol (2.5 mg). Subjective sedation was assessed by means of visual analogue scales (VAS) and objective sedation using a simple-reaction-time (SRT) task and a choice-reaction-time (CRT) task, code substitution (symbol digit substitution test (SDST)) and the peak velocity of saccadic eye movements (SEM). A verbal memory test (VMT) was administered to evaluate memory capacity. Apart from haloperidol, all drugs proved to impair performance on all five sedation indices. Contrary to the VAS, the objective measures yielded different response profiles. Two types of drug-effect patterns emerged: one for greater impairments in response speed (SRT, SEM) and one for greater impairments in information processing (CRT, SDST). Lorazepam and olanzapine impeded memory performance, whereas mirtazapine did not. With the use of standardized scores it proved possible to differentiate between the size of the effects of the drugs on the sedation and memory tests. To accurately assess the level and nature of sedation and to differentiate sedation from memory impairments different types of sedation measures are required. Besides studying the subjective effects, it is recommended to also test psychomotor responses and information processing speed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17092974     DOI: 10.1177/0269881106071550

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  7 in total

1.  Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses.

Authors:  Ricardo Alvarez-Jimenez; Ellen P Hart; Samantha Prins; Marieke de Kam; Joop M A van Gerven; Adam F Cohen; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

2.  Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation.

Authors:  Lenneke Schrier; Rob Zuiker; Frans W H M Merkus; Erica S Klaassen; Zheng Guan; Bert Tuk; Joop M A van Gerven; Ronald van der Geest; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2016-12-20       Impact factor: 4.335

3.  Antipsychotic-induced somnolence in mothers with schizophrenia.

Authors:  Mary V Seeman
Journal:  Psychiatr Q       Date:  2012-03

4.  An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.

Authors:  Anne Catrien Baakman; Ricardo Alvarez-Jimenez; Robert Rissmann; Erica S Klaassen; Jasper Stevens; Sebastiaan C Goulooze; Jeroen C G den Burger; Eleonora L Swart; Joop M A van Gerven; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2017-04-08       Impact factor: 4.335

5.  Using arterial spin labeling perfusion MRI to explore how midazolam produces anterograde amnesia.

Authors:  Peipeng Liang; Anna Manelis; Xiaonan Liu; Howard J Aizenstein; Ferenc Gyulai; Joseph J Quinlan; Lynne M Reder
Journal:  Neurosci Lett       Date:  2012-06-16       Impact factor: 3.046

6.  Effects of aripiprazole and haloperidol on neural activation during a simple motor task in healthy individuals: A functional MRI study.

Authors:  Rhianna Goozee; Owen O'Daly; Rowena Handley; Tiago Reis Marques; Heather Taylor; Grant McQueen; Kathryn Hubbard; Carmine Pariante; Valeria Mondelli; Antje A T S Reinders; Paola Dazzan
Journal:  Hum Brain Mapp       Date:  2016-12-23       Impact factor: 5.038

7.  No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model.

Authors:  Anne Catrien Baakman; Ricardo Alvarez-Jimenez; Gordon Loewen; Marieke L de Kam; Karen Broekhuizen; Dana C Hilt; Geert Jan Groeneveld
Journal:  Alzheimers Dement (N Y)       Date:  2019-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.